BACKGROUND AND PURPOSE: Red blood cell transfusion (RBCT) may increase the risk of thrombotic events (TE) in patients with subarachnoid hemorrhage (SAH) through changes induced by storage coupled with SAH-related hypercoagulability. We sought to investigate the association between RBCT and the risk of TE in patients with SAH. METHODS: 205 consecutive patients with acute, aneurysmal SAH admitted to the neurovascular intensive care unit of a tertiary care, academic medical center between 3/2008 and 7/2009 were enrolled in a retrospective, observational cohort study. TE were defined as the composite of venous thromboembolism (VTE), myocardial infarction (MI), and cerebral infarction noted on brain CT scan. Secondary endpoints included the risk of VTE, poor outcome (modified Rankin score 3-6 at discharge), and in-hospital mortality. RESULTS: 86/205 (42 %) received RBCT. Eighty-eight (43 %) had a thrombotic complication. Forty (34 %) of 119 non-transfused and 48/86 (56 %) transfused patients had a TE (p = 0.002). In multivariate analysis, RBCT was associated with more TE by [OR 2.4; 95 % CI (1.2, 4.6); p = 0.01], VTE [OR 2.3; 95 % CI (1.0, 5.2); p = 0.04], and poor outcome [OR 5.0; 95 % CI (1.9, 12.8); p < 0.01]. The risk of TE increased by 55 % per unit transfused when controlling for univariate variables. Neither mean nor maximum age of blood was significantly associated with thrombotic risk. CONCLUSIONS: RBCT is associated with an increased risk of TE and VTE in SAH patients. A dose-dependent relationship exists between number of units transfused and thrombosis. Age of blood does not appear to play a role.
BACKGROUND AND PURPOSE: Red blood cell transfusion (RBCT) may increase the risk of thrombotic events (TE) in patients with subarachnoid hemorrhage (SAH) through changes induced by storage coupled with SAH-related hypercoagulability. We sought to investigate the association between RBCT and the risk of TE in patients with SAH. METHODS: 205 consecutive patients with acute, aneurysmalSAH admitted to the neurovascular intensive care unit of a tertiary care, academic medical center between 3/2008 and 7/2009 were enrolled in a retrospective, observational cohort study. TE were defined as the composite of venous thromboembolism (VTE), myocardial infarction (MI), and cerebral infarction noted on brain CT scan. Secondary endpoints included the risk of VTE, poor outcome (modified Rankin score 3-6 at discharge), and in-hospital mortality. RESULTS: 86/205 (42 %) received RBCT. Eighty-eight (43 %) had a thrombotic complication. Forty (34 %) of 119 non-transfused and 48/86 (56 %) transfused patients had a TE (p = 0.002). In multivariate analysis, RBCT was associated with more TE by [OR 2.4; 95 % CI (1.2, 4.6); p = 0.01], VTE [OR 2.3; 95 % CI (1.0, 5.2); p = 0.04], and poor outcome [OR 5.0; 95 % CI (1.9, 12.8); p < 0.01]. The risk of TE increased by 55 % per unit transfused when controlling for univariate variables. Neither mean nor maximum age of blood was significantly associated with thrombotic risk. CONCLUSIONS: RBCT is associated with an increased risk of TE and VTE in SAHpatients. A dose-dependent relationship exists between number of units transfused and thrombosis. Age of blood does not appear to play a role.
Authors: P Nina; G Schisano; F Chiappetta; M Luisa Papa; E Maddaloni; A Brunori; F Capasso; M G Corpetti; F Demurtas Journal: Surg Neurol Date: 2001-04
Authors: Paul C Hébert; Dean Fergusson; Morris A Blajchman; George A Wells; Andrew Kmetic; Doug Coyle; Nancy Heddle; Marc Germain; Mindy Goldman; Baldwin Toye; Irwin Schweitzer; Carl vanWalraven; Dana Devine; Graham D Sher Journal: JAMA Date: 2003-04-16 Impact factor: 56.272
Authors: Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel Journal: Neurocrit Care Date: 2011-09 Impact factor: 3.210
Authors: Andrew M Naidech; Ali Shaibani; Rajeev K Garg; Isis M Duran; Storm M Liebling; Sarice L Bassin; Bernard R Bendok; Richard A Bernstein; H Hunt Batjer; Mark J Alberts Journal: Neurocrit Care Date: 2010-12 Impact factor: 3.210
Authors: Rajat N Moman; Daryl J Kor; Arun Chandran; Andrew C Hanson; Darrell R Schroeder; Alejandro A Rabinstein; Matthew A Warner Journal: J Crit Care Date: 2018-11-11 Impact factor: 3.425
Authors: Eric Zhou; Aaron Lord; Amelia Boehme; Nils Henninger; Adam de Havenon; Farhaan Vahidy; Koto Ishida; Jose Torres; Eva A Mistry; Brian Mac Grory; Kevin N Sheth; M Edip Gurol; Karen Furie; Mitchell S V Elkind; Shadi Yaghi Journal: Stroke Date: 2020-10-08 Impact factor: 7.914
Authors: Nino Stocchetti; Fabio S Taccone; Giuseppe Citerio; Paul E Pepe; Peter D Le Roux; Mauro Oddo; Kees H Polderman; Robert D Stevens; William Barsan; Andrew I R Maas; Geert Meyfroidt; Michael J Bell; Robert Silbergleit; Paul M Vespa; Alan I Faden; Raimund Helbok; Samuel Tisherman; Elisa R Zanier; Terence Valenzuela; Julia Wendon; David K Menon; Jean-Louis Vincent Journal: Crit Care Date: 2015-04-21 Impact factor: 9.097
Authors: Lisa Baumann Kreuziger; Gustaf Edgren; Ronald George Hauser; Daniel Zaccaro; Joseph Kiss; Matt Westlake; Donald Brambilla; Alan E Mast Journal: Am J Hematol Date: 2020-11-16 Impact factor: 10.047